LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying…
LaunchTrends: Ibrance (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
Probing Prescriber Preferences and Payer Strategies for Current and Emerging Agents in the EU5 Nearly 800,000 individuals were diagnosed with opioid addiction in the five major European markets…
Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs? Nine biologics are approved to treat rheumatoid arthritis (RA),…
A Survey of Psychiatrists and Interviews with Payers in the EU5 Despite being a leading preventable cause of morbidity and mortality in Europe, alcohol addiction is tremendously underdiagnosed and…
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease with rapid progression and high rates of mortality. If left untreated, life expectancy is less than three years; even…
The Impact of Premium-Priced Market Entrants on MCO-Run Medicare and Medicaid Plans The groundbreaking therapies for the Hepatitis C virus (HCV) promise high cure rates for millions of Americans…
U.S. Physician and Payer Insights on New and Recently Launched Therapies and on the Impact of Expanding Generics The chronic pain market is sizeable in terms of both dollars and the potential…
Amid Effective TNF-α Inhibitors, What Clinical Improvements Do Rheumatologists and Payers Expect from Emerging Therapies with a Different Mechanism of Action? Axial spondyloarthritis (Ax SpA) is…
How Will New Market Entrants Fare in the Rapidly Evolving Treatment Landscape? Affecting at least 170 million people worldwide, chronic hepatitis C virus (HCV) infections are a serious public…
Physician and Payer Perspectives on Prescribing and Patient Access China has long wrestled with an increasing prevalence in respiratory diseases that has accompanied its economic growth and…
What Clinical Improvements Will Differentiate Emerging Therapies in a Market with High Unmet Need and Rising Use of Microbiome-Based Treatments? Clostridium difficile infection (CDI) and…
Are new drug classes expected to address the considerable unmet need? Crohn’s disease (CD) is a chronic gastrointestinal inflammatory disorder affecting over 1 million people in the major…
How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically receive chemotherapy (…
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
